Ligand Pharmaceuticals Incorporated 13D and 13G filings for Viking Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-03-30 4:08 pm Sale | 2023-03-28 | 13D | Viking Therapeutics, Inc. VKTX | LIGAND PHARMACEUTICALS INC LGND | 3,616,077 4.600% | -2,449,003 (-40.38%) | Filing |
| 2023-02-09 4:30 pm Sale | 2023-02-06 | 13D | Viking Therapeutics, Inc. VKTX | LIGAND PHARMACEUTICALS INC LGND | 6,065,080 7.900% | -1,274,303 (-17.36%) | Filing |